C above pre-industrial levels. There were numerous extreme weather events globally, such as a heavy downpour in the Persian ...

A Santa Rosa family that made national headlines seven years ago when a judge allowed their daughter to receive cannabis oil to stop seizures in school, is now, again, battling to keep her in school.

Stoke Therapeutics (STOK) experienced a notable price movement last quarter, with shares rising 92%. This significant gain aligns with a backdrop of market trends and developments within the company.

In recent days, Biogen and its partners announced the FDA approval and October launch of LEQEMBI Iqlik, a subcutaneous, at-home formulation for early Alzheimer's disease, along with new positive ...

Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-label extension studies – – ...

What Happened? Shares of biotech company Biogen (NASDAQ:BIIB) jumped 4.8% in the afternoon session after the company and its ...

The FDA has also granted zorevunersen rare pediatric disease designation and Breakthrough Therapy Designation for the treatment of Dravet syndrome with a confirmed mutation not associated with gain-of ...

Biogen (BIIB) and Stoke Therapeutics (STOK) announced data from Phase 1/2a and open-label extension, OLE, studies of zorevunersen that support the ...

We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Biogen Inc. is one of them. Biogen Inc. (NASDAQ:BIIB), founded in 1978 and headquartered in Cambridge, ...

Encoded Therapeutics Inc., a clinical-stage biotechnology company developing genetic medicines for severe neurological disorders, today announced the U.S. Food and Drug Administration (FDA) has ...